University of Wisconsin-Madison

Introduction

The University of Wisconsin-Madison (UW-Madison) is a public research university and one of the founding members of the Association of American Universities. Founded in 1848, it is one of the oldest and most prestigious public universities in the United States. The university is home to world-renowned research programs in neuroscience and neurodegenerative diseases, particularly in Alzheimer’s disease, Parkinson’s disease, and related conditions.

The institution’s location in Madison, Wisconsin, has fostered a unique research environment that combines access to diverse patient populations, strong academic resources, and a collaborative culture that has produced landmark discoveries in neurodegenerative disease research. The Wisconsin Alzheimer’s Disease Research Center (WADRC) and the Wisconsin Registry for Alzheimer Prevention (WRAP) represent some of the most influential programs in the field.

Historical Development

Foundation and Early Growth

The University of Wisconsin-Madison was founded in 1848 as the state’s land-grant university. The early emphasis on scientific inquiry and practical education laid the foundation for the institution’s later research prominence. The Department of Neurology was established in the mid-20th century, marking the beginning of systematic neuroscience research.

Development of Neuroscience Research

Throughout the latter half of the 20th century, UW-Madison built its neuroscience research capabilities through strategic hiring and infrastructure investments. Key developments include:

• 1970s: Establishment of the neuroscience graduate program

• 1980s: Construction of the Waisman Center for brain research

• 1990s: Launch of the Alzheimer’s disease research program

• 2009: Establishment of the Wisconsin Alzheimer’s Disease Research Center

• 2010s: Growth of the Wisconsin Registry for Alzheimer Prevention

The Wisconsin Alzheimer’s Disease Research Center

The Wisconsin Alzheimer’s Disease Research Center (WADRC) was established in 2009 with funding from the National Institute on Aging, becoming one of 33 NIH-funded Alzheimer’s Disease Research Centers. The center has made seminal contributions to understanding preclinical Alzheimer’s disease and identifying biomarkers that enable early detection^{1The effect of Alzheimer's disease risk factors on plasma biomarkers2018 · Neurology · PMID 29728555Open reference}.

The WADRC’s mission encompasses:

• Research: Basic and clinical research on Alzheimer’s disease

• Training: Education of the next generation of researchers

• Outreach: Community engagement and education

• Clinical care: Assessment and care for patients and families

Research Infrastructure

Campus and Facilities

UW-Madison’s research facilities are among the most advanced in the world. The campus features purpose-built research space designed for interdisciplinary collaboration.

Wisconsin Alzheimer’s Disease Research Center

The WADRC occupies dedicated research space on the university campus, housing:

• Clinical research unit: Outpatient facilities for participant evaluation

• Biomarker laboratory: CSF and blood processing and analysis

• Neuroimaging suite: MRI and PET scanner access

• Data management: Secure data storage and analysis infrastructure

Waisman Center

The Waisman Center is one of the nation’s premier centers for developmental disabilities and neurodegenerative disease research. Established in 1973, it provides:

• Neuroimaging facilities: Advanced MRI and PET capabilities

• Stem cell research: Induced pluripotent stem cell facility

• Behavioral assessment: Specialized testing environments

• Core facilities: Shared resources for researchers

Center for Neurodegeneration and Repair

The Center for Neurodegeneration and Repair (CNR) brings together researchers from multiple departments to study:

• Parkinson’s disease mechanisms and therapeutics

• Alzheimer’s disease pathogenesis

• Traumatic brain injury and chronic neurodegeneration

• Alcohol-related brain damage

Research Centers and Programs

Alzheimer’s Disease Research Program

Overview

flowchart TD
    institutions_university_of_wis["University of Wisconsin-Madison"]
    style institutions_university_of_wis fill:#4fc3f7,stroke:#333,color:#000
    institutions_univers_0["Historical Development"]
    institutions_university_of_wis -->|"includes"| institutions_univers_0
    style institutions_univers_0 fill:#81c784,stroke:#333,color:#000
    institutions_univers_1["Foundation and Early Growth"]
    institutions_university_of_wis -->|"includes"| institutions_univers_1
    style institutions_univers_1 fill:#ef5350,stroke:#333,color:#000
    institutions_univers_2["Development of Neuroscience Research"]
    institutions_university_of_wis -->|"includes"| institutions_univers_2
    style institutions_univers_2 fill:#ffd54f,stroke:#333,color:#000
    institutions_univers_3["The Wisconsin Alzheimers Disease Research Cente"]
    institutions_university_of_wis -->|"includes"| institutions_univers_3
    style institutions_univers_3 fill:#ce93d8,stroke:#333,color:#000
    institutions_univers_4["Research Infrastructure"]
    institutions_university_of_wis -->|"includes"| institutions_univers_4
    style institutions_univers_4 fill:#4fc3f7,stroke:#333,color:#000
    institutions_univers_5["Campus and Facilities"]
    institutions_university_of_wis -->|"includes"| institutions_univers_5
    style institutions_univers_5 fill:#81c784,stroke:#333,color:#000

The Alzheimer’s disease research program at UW-Madison represents one of the nation’s most comprehensive efforts to understand preclinical Alzheimer’s disease and develop early intervention strategies. The program’s focus on early detection has yielded critical insights into disease progression and risk factors

Current Research Directions

Biomarker Studies

Researchers at UW-Madison have made substantial contributions to biomarker research:

Cerebrospinal Fluid Biomarkers

• Amyloid-beta (Aβ42, Aβ40) measurement

• Total tau and phospho-tau analysis

• Neurofilament light chain as neuronal injury marker

• Novel biomarker discovery through proteomics

Blood-Based Biomarkers

• Development of plasma Aβ assays

• Ultra-sensitive tau measurement techniques

• Exploration of extracellular vesicle biomarkers

Imaging Biomarkers

• Amyloid PET with florbetapir and flutemetamol

• Tau PET with flortaucipir

• Structural MRI for hippocampal volume

• Functional connectivity MRI^{2CSF biomarkers and brain structure in midlife2019 · Neurobiol Aging · PMID 30953892Open reference}

Risk Factor Research

The program has identified multiple modifiable risk factors:

• Cardiovascular health: Blood pressure, diabetes, and vascular risk

• Lifestyle factors: Exercise, diet, and cognitive engagement

• Metabolic factors: Obesity and metabolic syndrome

• Sleep quality: Sleep disorders and circadian dysfunction^{3Do lifestyle factors influence Alzheimer's disease biomarkers?2021 · Alzheimer's Dement · PMID 33410982Open reference}

Clinical Research

The clinical research program encompasses:

• WRAP study: Wisconsin Registry for Alzheimer Prevention

• Treatment trials: Disease-modifying and symptomatic therapies

• Prevention studies: Trials in cognitively normal individuals

• Observational studies: Natural history and biomarker studies

The Wisconsin Registry for Alzheimer Prevention (WRAP)

The Wisconsin Registry for Alzheimer Prevention is one of the largest and most deeply characterized research cohorts of cognitively normal middle-aged adults at risk for Alzheimer’s disease. Launched in 2003, WRAP has enrolled over 1,700 participants who undergo comprehensive assessments every two years^{4Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}.

WRAP has contributed to major findings including:

• Identification of earliest biomarkers of preclinical Alzheimer’s

• Understanding of lifestyle and genetic risk factors

• Development of cognitive reserve measures

• Characterization of subjective cognitive decline

Notable Publications

Research from UW-Madison has appeared in leading journals:

• Neurology

• Alzheimer’s & Dementia

• Journal of Nuclear Medicine

• Neurobiology of Aging

• Nature Reviews Neurology

Parkinson’s Disease Research Program

Overview

The Parkinson’s disease research program at UW-Madison has developed into a comprehensive effort spanning basic science, clinical research, and therapeutic development. The program benefits from the institution’s expertise in protein aggregation, dopamine biology, and neuroimaging.

Research Focus Areas

Alpha-Synuclein Biology

Researchers study the normal function and pathological aggregation of alpha-synuclein:

• Aggregation mechanisms: Understanding fibril formation and propagation

• Cellular models: In vitro and in vivo models of toxicity

• Strain characterization: Distinct aggregate conformations

Dopamine Neurobiology

The program investigates dopamine neuron biology:

• Survival mechanisms: Factors promoting dopaminergic neuron survival

• Degeneration pathways: Understanding cell death mechanisms

• Therapeutic targets: Novel neuroprotective approaches

Clinical Research

The clinical research program includes:

• Movement Disorder Clinic: Comprehensive patient care

• Deep brain stimulation: Surgical program and programming

• Clinical trials: Novel therapeutic agents and devices

• Biomarker studies: Identification of progression markers

Non-Motor Symptoms Research

UW-Madison researchers have contributed substantially to understanding non-motor symptoms:

• Sleep disorders: REM sleep behavior disorder, insomnia

• Cognitive impairment: Executive dysfunction and dementia

• Psychiatric manifestations: Depression, anxiety, psychosis

• Autonomic dysfunction: Gastrointestinal and cardiovascular issues

Key Researchers

Leadership

Faculty Members

• Dr. Kimberly A. Mueller: Cognitive aging, intervention studies

• Dr. Aaron M. P. Greene: Neuroimaging, computational methods

• Dr. Lindsay R. Clark: Blood biomarkers, precision medicine

• Dr. Hans J. T. Johnson: Sleep and neurodegeneration

Sterling C. Johnson Laboratory

Dr. Sterling Johnson leads the WADRC and has been instrumental in characterizing preclinical Alzheimer’s disease through the WRAP cohort. His research has focused on identifying biomarker changes that occur decades before clinical symptoms appear. The Johnson laboratory has published extensively on the relationship between amyloid and tau pathology and cognitive decline, demonstrating that biomarker changes can predict future cognitive impairment even in cognitively normal individuals^{1The effect of Alzheimer's disease risk factors on plasma biomarkers2018 · Neurology · PMID 29728555Open reference5Biomarkers in preclinical AD2020 · PMID 32040185Open reference}. Current research explores multi-modal biomarker approaches combining imaging, CSF, and blood-based measures.

Barbara B. Bendlin Research Program

Dr. Bendlin’s research examines how lifestyle factors influence Alzheimer’s disease biomarkers and risk. Her work has shown that cardiovascular health, exercise, diet, and other modifiable factors can influence brain aging and Alzheimer’s disease pathology^{2CSF biomarkers and brain structure in midlife2019 · Neurobiol Aging · PMID 30953892Open reference3Do lifestyle factors influence Alzheimer's disease biomarkers?2021 · Alzheimer's Dement · PMID 33410982Open reference}. The Bendlin laboratory uses neuroimaging and biomarker approaches to understand how lifestyle interventions may protect against neurodegeneration.

Matthew R. Anderson Parkinson’s Research

Dr. Anderson chairs the Department of Neurology and leads the Parkinson’s disease research program. His research focuses on understanding the mechanisms of dopaminergic neuron degeneration and developing neuroprotective strategies. The Anderson laboratory investigates alpha-synuclein biology, mitochondrial dysfunction, and neuroinflammation in Parkinson’s disease pathogenesis.

Wisconsin Registry for Alzheimer Prevention (WRAP)

The Wisconsin Registry for Alzheimer Prevention is one of the largest and most deeply characterized research cohorts of cognitively normal middle-aged adults at risk for Alzheimer’s disease. Launched in 2003, WRAP has enrolled over 1,700 participants who undergo comprehensive assessments every two years^{4Wisconsin Registry for Alzheimer Prevention2019 · PMID 31171447Open reference}.

Study Design and Population

WRAP participants are recruited from throughout Wisconsin, with an emphasis on including individuals with a family history of Alzheimer’s disease. The cohort includes:

• Age range: 40-65 years at enrollment

• Cognitive status: Cognitively normal at baseline

• Family history: Approximately 70% have a parent or sibling with AD

• Assessment schedule: Comprehensive testing every 2 years

Key Findings

WRAP has contributed to major findings including:

• Identification of earliest biomarkers of preclinical Alzheimer’s

• Understanding of lifestyle and genetic risk factors

• Development of cognitive reserve measures

• Characterization of subjective cognitive decline

• Sleep and circadian influences on biomarkers^{6Sleep and Alzheimer's disease biomarkers2023 · Alzheimer's & Dementia}

Biomarker Contributions

WRAP researchers have made significant contributions to biomarker science:

Amyloid PET Imaging: Longitudinal amyloid PET imaging has characterized the temporal relationship between amyloid deposition and downstream tau pathology and cognitive decline^{2CSF biomarkers and brain structure in midlife2019 · Neurobiol Aging · PMID 30953892Open reference}0. Studies show that amyloid accumulation begins decades before symptoms and follows a predictable trajectory.

CSF Biomarkers: WRAP has contributed to understanding how CSF biomarkers change in preclinical AD, including amyloid, tau, and neurofilament light chain measurements^{2CSF biomarkers and brain structure in midlife2019 · Neurobiol Aging · PMID 30953892Open reference}1. These studies have informed biomarker cutoff values and diagnostic criteria.

Blood Biomarkers: UW-Madison researchers have been at the forefront of developing blood-based biomarkers, comparing plasma and CSF measures and validating ultra-sensitive assays for clinical use.

Training and Education

Graduate Programs

UW-Madison offers comprehensive neuroscience training:

• PhD in Neuroscience: Four-year program with neurodegeneration track

• PhD in Comparative Biomedical Sciences: Translational research focus

• Medical Scientist Training Program: MD/PhD training

Clinical Training

• Neurology residency: Four-year program with movement disorders track

• Behavioral neurology fellowship: Cognitive disorders training

• Movement disorders fellowship: Advanced clinical training

Postdoctoral Training

The institution supports postdoctoral researchers through:

• Individual fellowship opportunities

• Institutional training grants

• Career development programs

International Collaborations

Academic Partnerships

UW-Madison maintains collaborations with leading institutions:

• Washington University St. Louis: ADNI and biomarker studies

• University of Minnesota: Regional collaboration

• University of California, San Francisco: Parkinson’s research

• Mayo Clinic Rochester: Clinical research partnerships

• Banner Alzheimer’s Institute: Prevention trials

Research Consortia

The institution participates in national and international networks:

• Alzheimer’s Disease Neuroimaging Initiative (ADNI): Founding member

• Alzheimer’s Disease Sequencing Project: Genetic studies

• International Parkinson’s Disease Genomics Consortium: Genetic research

• Knight Alzheimer Disease Research Centers: Collaborative network

Industry Partnerships

UW-Madison collaborates with pharmaceutical companies:

• Clinical trials: Multiple therapeutic programs

• Biomarker development: Companion diagnostic development

• Preclinical collaboration: Drug discovery partnerships

Achievements and Impact

Major Contributions

UW-Madison researchers have made significant contributions:

1. Preclinical AD characterization: Defining earliest disease stages

2. Biomarker development: Pioneering CSF and imaging approaches

3. Risk factor identification: Lifestyle and genetic determinants

4. Cognitive reserve research: Understanding resilience mechanisms

Research Output

The institution’s research productivity includes:

• 150+ publications annually in neurodegenerative disease research

• 40+ active clinical trials

• $40+ million in annual research funding

Future Directions

Strategic Priorities

UW-Madison has identified key research priorities:

1. Early intervention: Development of prevention strategies

2. Precision medicine: Biomarker-guided treatment approaches

3. Lifestyle interventions: Non-pharmacological risk reduction

4. Digital health: Remote monitoring and digital biomarkers

Emerging Research Areas

• Alpha-synuclein PET: Development of imaging agents

• Multi-omic approaches: Integration of genomic, proteomic data

• Cell therapy: Stem cell approaches to neuronal replacement

• AI/ML: Computational models for prediction and diagnosis

Clinical Services

Outpatient Services

UW-Madison provides specialized clinics:

• Memory Disorders Clinic: Comprehensive dementia evaluation

• Movement Disorder Clinic: Parkinson’s disease care

• Sleep Disorders Clinic: Sleep and neurodegeneration

• General Neurology Clinic: Comprehensive care

Diagnostic Services

• Neuroimaging: MRI, CT, PET

• Neuropsychology: Comprehensive cognitive testing

• Neurophysiology: EEG, EMG

• Laboratory: CSF analysis, genetic testing

Clinical Trials Program

UW-Madison maintains an active clinical trials program for neurodegenerative diseases, participating in trials across all phases of drug development.

Alzheimer’s Disease Trials

The WADRC and Memory Disorders Clinic participate in numerous Alzheimer’s disease clinical trials:

Disease-Modifying Therapies: UW-Madison has been a key site for anti-amyloid antibody trials, including lecanemab and donanemab studies. The institution contributed significantly to the CLARITY-AD and TRAILBLAZER trials, evaluating whether amyloid removal translates to clinical benefit.

Tau-Targeting Therapies: The institution participates in trials of anti-tau antibodies and small molecule inhibitors targeting tau aggregation. These studies examine whether interrupting tau propagation can slow disease progression.

Prevention Trials: Given the focus on preclinical AD through WRAP, UW-Madison is well-positioned for prevention trials in at-risk individuals. Studies examine whether interventions before symptom onset can delay or prevent cognitive decline.

Neuroprotective Strategies: Trials testing compounds aimed at protecting neurons from various injury pathways, including oxidative stress, excitotoxicity, and neuroinflammation.

Parkinson’s Disease Trials

The Movement Disorders program conducts clinical trials including:

Alpha-Synuclein-Targeting Therapies: Participation in trials of monoclonal antibodies targeting aggregated alpha-synuclein, including PRX002 and related agents. These therapies aim to reduce pathological protein burden and slow disease progression.

LRRK2 Inhibitors: As LRRK2 is one of the most common genetic causes of PD, UW-Madison participates in trials of LRRK2 kinase inhibitors aimed at developing disease-modifying treatments for genetic and idiopathic PD.

Deep Brain Stimulation: Studies optimizing stimulation parameters, exploring novel targets, and evaluating closed-loop stimulation approaches that respond to patient symptoms in real-time.

Symptomatic Therapies: Trials of novel dopaminergic agents, including extended-release formulations and combination therapies for motor and non-motor symptoms.

Clinical Research Infrastructure

UW-Madison provides comprehensive infrastructure for clinical research:

• Clinical Trials Unit: Dedicated staff for protocol implementation

• Regulatory Support: IRB oversight and compliance monitoring

• Data Management: Electronic data capture and quality control

• Biomarker Core: Sample processing and storage

• Imaging Center: MRI and PET for research protocols

Community Engagement

Patient Advocacy

UW-Madison works with patient organizations:

• Alzheimer’s Association: Wisconsin chapter partnership

• Parkinson’s Foundation: Support groups and education

• Wisconsin Alzheimer’s Institute: Statewide resources

Public Education

The institution provides:

• Community lectures: Brain health education

• Memory screenings: Free cognitive assessments

• Caregiver support: Programs for families

• Health fairs: Community outreach

External Links

• University of Wisconsin-Madison: UW-Madison

• Wisconsin Alzheimer’s Disease Research Center: WADRC

• Waisman Center: Waisman

• Wisconsin Registry for Alzheimer Prevention: WRAP

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

• Tau Protein

• Alpha-Synuclein

• Wisconsin Alzheimer’s Disease Research Center

• Amyloid PET Imaging

• Cognitive Reserve